Trinity Biotech PLC reports results for the quarter ended in March - Earnings Summary

Trinity Biotech

30/06/2022 15:32

* Trinity Biotech PLC  TRIB.OQ  reported a quarterly
adjusted loss
of 50 cents​​ per share for the quarter ended in March. The lone
analyst forecast for the quarter was for a loss of 4 cents per
share.
    * Revenue fell 26.6% to $18.78 million from a year ago; 
analysts
expected $20.00 million. 
    * Trinity Biotech PLC's reported EPS for the quarter was a
loss
of 50 cents​.
    * The mean earnings estimate of analysts had fallen by
about 33.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Trinity Biotech PLC shares had risen by 23.6% this
quarter and
lost 8.4% so far this year.
    * Wall Street's median 12-month price target for Trinity
Biotech
PLC is $4.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated June 30 at 02:32 p.m.  ​All
figures in US dollars unless otherwise stated